Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA expands PharmaEssentia's Besremi (ropeginterferon alfa-2b) label to include essential thrombocythemia regardless of genotype
Protein therapy, cancer, interferon, essential thrombocythemia, myeloproliferative neoplasms, FDA approval - Read more

Takeda, Protagonist Therapeutics' Mimrylo (rusfertide) wins FDA approval for polycythemia vera following Ph3 success
Peptide therapy, cancer, hepcidin mimetic, polycythemia vera, hematocrit regulation - Read more

FDA approves Stelara (ustekinumab) for pediatric moderately to severely active ulcerative colitis in patients aged 2 and older
Antibody, autoimmune, monoclonal antibody, ulcerative colitis, pediatric patients, IL-12/IL-23 inhibitor - Read more

Mission Therapeutics, NeuraLight partner to deploy brain function biomarkers in multinational Parkinson's disease trial
Research collaboration, neurological, small molecule, diagnostics, digital health - Read more

CREATE Medicines, WestGene Biopharma collaborate to advance in vivo CAR therapies using targeted LNP delivery technology
Research collaboration, cell therapy, LNP technology, autoimmune, oncology, gene therapy - Read more

Heidelberg Pharma, Huadong Medicine sign new collaboration to jointly develop next-generation ADCs including bispecific formats
Co-development, antibody drug conjugates, oncology, drug discovery, R&D - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Jazz Pharmaceuticals' Ziihera (zanidatamab) achieves second overall survival win in Ph3 HER2-positive gastroesophageal adenocarcinoma trial
Antibody, cancer, bispecific antibody, gastric cancer, HER2 - Read more

AstraZeneca's AZD5462 (oral relaxin agonist) shows promise in Ph2 trial for chronic heart failure
Small molecule, cardiovascular, heart failure, relaxin agonist, RXFP1 - Read more

Arrowhead Pharmaceuticals' Redemplo (plozasiran) Ph3 data back label expansion bid for severe hypertriglyceridemia
RNA interference, metabolic, antisense oligonucleotide, hypertriglyceridemia, APOC3 target, pancreatitis - Read more

Quoin Pharmaceuticals reports positive Ph2/3 interim data for QRX003 in Netherton Syndrome
Small molecule, rare disease, topical therapy, Netherton syndrome, orphan disease - Read more

Electra Therapeutics files IPO to advance immunology and cancer pipeline assets
Immunology, rare disease, antibody, clinical-stage, oncology - Read more

Quoin Pharmaceuticals plans $50M private placement for rare and orphan disease clinical development
Rare disease, specialty pharmaceutical, clinical-stage, small molecule - Read more

Somerset Pharma expands New Jersey facilities, adding nasal spray medicine production line for U.S. patients
Nasal spray, generic medicines, operational, manufacturing expansion - Read more

Eli Lilly to acquire Merida Biosciences for up to $2.9B, expanding autoimmune and allergic disease pipeline
Precision degradation platform, autoimmune, strategic, major transaction - Read more

BioMarin wins patent settlement with Ascendis Pharma, securing 18–20% royalties on Ascendis Pharma's Yuviwel achondroplasia drug
Small molecule, rare disease, royalties, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

BioNTech halts Ph2 trial of (autogene cevumeran) mRNA vaccine in resected colorectal cancer due to futility
Vaccine, cancer, mRNA vaccine, colorectal cancer, personalized neoantigen therapy, monotherapy - Read more

B. Braun recalls multiple IV solution lots over iron oxide contamination amid wave of similar Baxter recalls
IV solution, cardiovascular, operational, safety recall - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here